{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"DLT is defined as adverse events (AEs) that occur within 21 days following JCARH125 infusion and meet any of the following criteria:\n\n* Treatment-emergent Grade ≥3 allergic reactions related to JCARH125;\n* Treatment-emergent Grade 3 seizures, regardless of attribution, that do not resolve to Grade ≤2 within 3 days in participants who have no evidence of central nervous system (CNS) involvement of Multiple Myeloma or other CNS pathology;\n* Treatment-emergent autoimmune toxicity Grade ≥3, regardless of attribution (excluding B-cell aplasia);\n* Treatment-emergent Grade 3 CRS that does not resolve to Grade ≤2 within 72 hours;\n* Any other treatment-emergent Grade 3 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days;\n* Any treatment-emergent Grade 4 AE related to JCARH125 that does not resolve to Grade ≤2 within 7 days;\n* Treatment-emergent Grade 4 Cytokine Release Syndrome of any duration;\n* Any treatment-emergent Grade 5 toxicity not due to the underlying malignancy","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who have either experienced a DLT or were followed for the full DLT evaluation period in phase 1","reportingStatus":"POSTED","timeFrame":"From day 1 to day 22 following JCARH125 infusion (Up to 21 days)","title":"Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1","type":"PRIMARY","unitOfMeasure":"Participants"}